G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer

PURPOSE: The combination of targeting the CDK4/6 and estrogen receptor (ER) signaling pathways with palbociclib and fulvestrant is a proven therapeutic strategy for the treatment of ER-positive breast cancer. However, the poor physicochemical properties of fulvestrant require monthly intramuscular i...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Breast Cancer Res Treat
Main Authors: Andreano, Kaitlyn J., Wardell, Suzanne E., Baker, Jennifer G., Desautels, Taylor K., Baldi, Robert, Chao, Christina A., Heetderks, Kendall A., Bae, Yeeun, Xiong, Rui, Tonetti, Debra A., Gutgesell, Lauren M., Zhao, Jiong, Sorrentino, Jessica A., Thompson, Delita A., Bisi, John E., Strum, Jay C., Thatcher, Gregory R. J., Norris, John D.
Format: Artigo
Sprog:Inglês
Udgivet: Springer US 2020
Fag:
Preclinical Study
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7103015/
https://ncbi.nlm.nih.gov/pubmed/32130619
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-020-05575-9
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker